The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases

Relationship Between Handgrip Strength and Nonalcoholic Fatty Liver Disease: Nationwide Surveys

BACKGROUND

The association of handgrip strength with nonalcoholic fatty liver disease (NAFLD) has not been studied yet. This study investigated the relationship between handgrip strength and NAFLD in South Korean adults.

METHODS

Referring to the Korea National Health and Nutrition Examination Survey 2014 and 2015 database, South Korean adults (n = 8001, women: 55.5%) aged 19-80 years having complete data were considered for this study. Relative handgrip strength (RHGS) [average handgrip strength of both hands divided by body mass index (BMI)], hepatic steatosis index (HSI), BMI, and components of metabolic syndrome were measured. Demographics, treatment of concurrent illnesses, and health-related behaviors were assessed by using standardized questionnaires. NAFLD was defined by the HSI >36.0, alcohol consumption <20 grams/day, and negative biomarkers for chronic hepatitis B and C.

RESULTS

The prevalence of NAFLD was 30.3% ± 0.7%. Complex sample logistic regression analysis revealed that individuals with lower RHGS [per 1 standard deviation (SD) decrease] manifested higher odds of suffering from NAFLD (adjusted odds ratio: 1.47, 95% confidence interval: 1.35-1.60). Furthermore, lower RHGS was associated with higher odds for NAFLD throughout the strata of sex, age group, education, BMI category, metabolic syndrome, treatment history of illnesses, smoking status, alcohol consumption, or physical activity. The odds for NAFLD increased in the range of 1.40-1.63 with 1 SD decrease in RHGS according to the strata.

CONCLUSIONS

This study of South Korean adults suggests that lower handgrip strength is associated with NAFLD regardless of sociodemographic characteristics, weight status, metabolic syndrome, concurrent illnesses, and lifestyle.

Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin

Hepatosteatosis is a disease present worldwide, which presents a number of health problems. Recently, thiazolidinedione (TZD) has been used as a therapy for lipid disorders. The present study demonstrates the potential of TZD as a treatment for hepatosteatosis and its mechanism of action, particularly focusing on its role in lipid metabolism. A total of 60 (80-90 g) rats were divided into three groups: A normal group with a standard diet, a high-fat, high-carbohydrate diet (HFCD) group or a HFCD+TZD group (n=20/group). The HFCD induced hepatosteatosis over a period of 12 weeks and the HFCD+TZD group were administered TZD in weeks 13-16. Blood and tissue samples were collected to measure hepatic function, the lipid profile, metabolism and hormone biomarkers, including serum triglyceride (TG), lipoprotein lipase (LPL), stearoyl-CoA desaturase (SCD-1), leptin and resistin. The HFCD-fed rats exhibited a significant increase in serum TG, total cholesterol, low-density lipoproteins, alanine transaminase and bilirubin compared with the normal group as well as a significant decrease in high-density lipoprotein. In addition, serum leptin and resistin were significantly elevated in the HFCD group compared with the normal group. The administration of TZD significantly increased SCD-1 activity and significantly inhibited LPL activity. It also attenuated the changes in the lipid profiles and normalized serum leptin and resistin levels. The results of the present study indicated that HFCD induced lipid abnormalities associated with hypertriglyceridemia, hypercholesterolemia and hepatosteatosis. These changes resulted from disruption to leptin and resistin, which may be due to alterations in LPL and SCD-1 activity. TZD mitigated the effects of HFCD-induced hepatosteatosis, indicating a possible regulatory effect of TZD in the development of hepatosteatosis. The authors suggest that the manipulation of SCD-1 and lipase by TZD may be useful as a treatment for hepatosteatosis.